Immunotherapy plus chemo before surgery: a new hope for breast cancer?
NCT ID NCT06908668
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding an immunotherapy drug called adebrelimab to chemotherapy, with or without radiation, before surgery can help eliminate HER2-negative locally advanced breast cancer. About 170 women aged 18-70 will participate. The main goal is to see if the cancer completely disappears by the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Adebrelimab (an immunotherapy drug) combined with chemotherapy (albumin-bound paclitaxel, epirubicin, cyclophosphamide) and optionally radiotherapy
- What this could lead to
- If successful, this approach could improve the chance of eliminating all cancer before surgery, potentially leading to better long-term outcomes for patients with this type of breast cancer.
- What could go wrong
- This is a Phase 2 trial with only 170 participants, so results are preliminary. The added treatments may cause more side effects, and it's unknown if the combination will work better than standard therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE LOCALLY ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, China